tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Ashiq Mubarack, 2 are a BUY (66.67%), 1 are a HOLD (33.33%).
Analyst Ashiq Mubarack, currently employed at CITI, carries an average stock price target met ratio of 50% that have a potential upside of 145.1% achieved within 87 days.
Ashiq Mubarack’s has documented 5 price targets and ratings displayed on 1 stocks.
Most recent stock forecast was given on MRSN, Mersana Therapeutics at 27-Aug-2024.
Analyst best performing recommendations are on MRSN (MERSANA THERAPEUTICS).
The best stock recommendation documented was for MRSN (MERSANA THERAPEUTICS) at 12/4/2023. The price target of $125 was fulfilled within 87 days with a profit of $74 (145.1%) receiving and performance score of 16.68.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 14-Aug-2025
$30.75
$1.67 (5.74%)
$36
10 months 17 days ago
(13-Nov-2025)
0/2 (0%)
$3.32 (12.10%)
Buy Since 13-Aug-2025
$17
10 months 17 days ago
(13-Nov-2025)
1/1 (100%)
$10.19 (149.63%)
92
Buy Since 16-May-2025
$30
$0.92 (3.16%)
1 years 1 months 16 days ago
(14-Aug-2025)
1/3 (33.33%)
$22.58 (304.31%)
1072
Buy Since 06-May-2025
$175
1 years 4 months 24 days ago
(06-May-2025)
5/8 (62.5%)
$39 (28.68%)
550
Buy Since 27-Aug-2024
$125
2 years 1 months 3 days ago
(27-Aug-2024)
1/2 (50%)
$74 (145.10%)
87
What Year was the first public recommendation made by Ashiq Mubarack?
